Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Individuals with chronic HCV genotype 1 infection~* Documented as treatment experienced with a direct acting antiviral-containing regimen without achieving sustained viral response~* Absence of cirrhosis or presence of compensated cirrhosis~* Screening laboratory values within defined thresholds~* Must use specific contraceptive methods if female of childbearing potential or sexually active male~Key Exclusion Criteria:~* Co-infection with HIV or hepatitis B virus (HBV)~* Current or prior history of clinical hepatic decompensation~* Chronic use of systemic immunosuppressive agents~* History of clinically significant illness or any other medical disorder that may interfere with individual's treatment, assessment or compliance with the protocol~* Pregnant or a nursing female~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL/VOX (Type: EXPERIMENTAL): SOF/VEL/VOX for 12 weeks
- SOF/VEL/VOX + RBV (Type: EXPERIMENTAL): SOF/VEL/VOX + RBV for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).